Germany funds psilocybin study with €2.6m
Germany’s Federal Ministry of Education and Research (BMBF) has granted €2.6m to a study investigating the potential effectiveness of psilocybin as an antidepressant treatment for people who cannot tolerate conventional treatments. The “Efficacy and safety of Psilocybin in treatment-resistant major depression” (EpisoDE) study was launched by the Central Institute for Mental Health (CIMH) Mannheim in 2021. The purpose of this study is to determine whether psilocybin is an effective treatment for people with severe depression.
